As research continues to advance, the ability to detect and intervene in neurodegenerative disease at its earliest stages will become an increasingly important component of clinical care, by Caroline McDermott
Neurodegenerative diseases—including Parkinson’s disease (PD), Alzheimer’s disease (AD), and related disorders—are among the leading causes of disability and dependency worldwide. Their defining feature is progressive neuronal dysfunction and loss, resulting in cumulative motor, cognitive, and behavioural decline. For clinicians in both primary and specialist care, early awareness is increasingly recognised as central to effective management, reflecting a broader shift in how these conditions are conceptualised: not as late-stage clinical syndromes, but as long-evolving biological processes.
The evolving model of neurodegeneration
The traditional diagnostic model of neurodegenerative disease has been largely reactive, identifying disease at the point of overt clinical manifestation. However, advances in neuropathology, imaging, and biomarker research have demonstrated that the underlying disease processes begin many years—often decades—before diagnosis. In Parkinson’s disease, for example, significant dopaminergic neuronal loss has already occurred by the time motor symptoms emerge, reflecting a prolonged preclinical trajectory.
This has led to a reconceptualisation of neurodegenerative disease as a continuum encompassing preclinical, prodromal, and clinical phases. Importantly, this model introduces a window of opportunity for earlier identification and intervention, with significant implications for both clinical practice and research.
Clinical importance of early awareness
Earlier diagnosis and improved care pathways
Timely diagnosis remains a key challenge in neurodegenerative disease. In Parkinson’s disease, diagnosis is still primarily clinical, and early presentations may be subtle or atypical. By the time classical motor features such as bradykinesia and rigidity are evident, substantial neuronal loss has already occurred.
Earlier recognition allows clinicians to initiate appropriate symptomatic treatment, reduce misdiagnosis, and provide patients with clearer prognostic information. It also facilitates earlier integration of multidisciplinary care, which is increasingly recognised as essential in managing both motor and non-motor disease burden.
The prodromal phase: a critical clinical window
One of the most important developments in recent years has been the growing understanding of the prodromal phase of neurodegenerative disease, particularly in Parkinson’s disease. This phase is characterised by early, often non-specific symptoms and biological changes that precede the onset of classical motor or cognitive features.
Evidence indicates that the pathological processes underlying Parkinson’s disease begin many years before diagnosis, with neuronal loss and associated mechanisms—such as protein aggregation and neuroinflammation—already underway decades earlier . The prodromal phase therefore represents a crucial window during which disease may be detectable, albeit with uncertainty.
Clinical features of the prodrome
The prodromal phase is typically dominated by non-motor symptoms, reflecting early involvement of multiple neural systems beyond the dopaminergic pathways. Common features include:
- Olfactory dysfunction, often one of the earliest detectable changes
- REM sleep behaviour disorder (RBD), strongly associated with future synucleinopathies
- Gastrointestinal dysfunction, particularly constipation, which may precede diagnosis by many years
- Mood disorders, including depression and anxiety
- Subtle cognitive changes, particularly in executive function
These features are individually non-specific, but their co-occurrence—particularly in older adults—can indicate an evolving neurodegenerative process. Increasingly, research frameworks conceptualise the prodromal phase as part of a spectrum that includes “at-risk” and “preclinical” states, reflecting varying degrees of likelihood of progression to overt disease .
Predictive markers and risk stratification
Among prodromal markers, REM sleep behaviour disorder has emerged as one of the most robust clinical predictors of neurodegenerative disease, with a high proportion of affected individuals eventually developing Parkinson’s disease or related disorders. Similarly, combinations of clinical features and risk factors can be used to estimate the probability of prodromal disease, as reflected in research criteria developed by international expert groups.
Advances in biomarker research are further refining this process. Imaging modalities, such as dopamine transporter imaging, and emerging fluid biomarkers (including α-synuclein assays) are increasingly being investigated as tools to identify early disease. In parallel, digital and computational approaches—including machine learning and multimodal data analysis—are showing promise in detecting subtle physiological and behavioural changes prior to clinical diagnosis .
However, despite these advances, the identification of prodromal disease remains probabilistic rather than definitive. Sensitivity and specificity vary across modalities, and most approaches are not yet validated for routine clinical screening.
Pathophysiological insights
The prodromal phase has also provided important insights into disease mechanisms. The presence of early non-motor symptoms supports models of disease spread beyond the substantia nigra, including hypotheses involving the gut–brain axis and peripheral nervous system involvement. Gastrointestinal symptoms, for example, may reflect early pathology in the enteric nervous system, with subsequent propagation to central structures.
In addition, increasing attention has been paid to the role of neuroinflammation and immune dysregulation in early disease. Microglial activation and systemic immune changes have been observed in prodromal and early-stage Parkinson’s disease, suggesting that inflammatory processes may contribute to disease initiation and progression .
Clinical implications
For clinicians, recognising the prodromal phase presents both opportunities and challenges. Patients may present with isolated symptoms—such as sleep disturbance or constipation—that do not immediately suggest a neurological diagnosis. However, a pattern-based approach, informed by awareness of prodromal features, can help identify individuals at higher risk.
Early recognition allows for:
- Closer clinical monitoring and follow-up
- Earlier referral to specialist services
- Management of non-motor symptoms that significantly impact quality of life
- Consideration of enrolment in research studies or early-phase clinical trials
At the same time, clinicians must navigate the uncertainty inherent in prodromal diagnosis, balancing vigilance with the risk of overdiagnosis and patient anxiety.
Implications for disease modification
The increasing focus on early awareness is closely linked to the pursuit of disease-modifying therapies. To date, most treatments for neurodegenerative diseases remain symptomatic. However, there is growing consensus that interventions aimed at slowing or preventing disease progression will need to be applied early in the disease course.
Recent research highlights that many clinical trials may have failed, in part, because interventions were introduced too late—after substantial neuronal loss had already occurred . As a result, there is a shift towards targeting individuals in preclinical or prodromal stages, supported by advances in biomarker development and risk stratification.
This approach aligns with broader trends in medicine towards prevention and precision care, where interventions are tailored to individual risk profiles and disease biology.
Improving patient outcomes
Even in the absence of definitive disease-modifying therapies, early awareness has clear benefits for patient care. Non-motor symptoms, which often dominate the early and prodromal phases, can significantly affect quality of life and are frequently under-recognised in routine clinical practice.
Earlier diagnosis enables timely intervention with pharmacological and non-pharmacological therapies, including physiotherapy, occupational therapy, and psychological support. It also allows for more effective patient education, shared decision-making, and long-term care planning.
Challenges and limitations
Despite its importance, early awareness is not without limitations. The heterogeneity of neurodegenerative disease means that early symptoms are often non-specific and overlap with other conditions. Diagnostic uncertainty is therefore inherent, particularly in the prodromal phase.
There are also ethical considerations associated with identifying individuals at risk of developing a progressive neurological disorder in the absence of definitive preventive therapies. Clinicians must balance the potential benefits of early recognition with the risks of anxiety, over-investigation, and unnecessary medicalisation.
The role of clinicians
General practitioners play a critical role in recognising early and prodromal features, given their longitudinal relationships with patients and ability to detect subtle changes over time. Specialists, meanwhile, are increasingly focused on refining diagnostic criteria, integrating biomarkers, and developing personalised approaches to care.
Collaboration between primary and secondary care is essential to ensure continuity, optimise management, and support patients across the disease trajectory.
Conclusion
Neurodegenerative diseases are increasingly understood as long-evolving processes with identifiable early stages. The recognition of the prodromal phase, particularly in Parkinson’s disease, represents a major advance in our clinical framework.
For clinicians, early awareness is integral to modern practice. It enables earlier diagnosis, supports more comprehensive care, and aligns with the emerging goal of disease modification. As research continues to advance, the ability to detect and intervene in neurodegenerative disease at its earliest stages will become an increasingly important component of clinical care. 
<
Leave a Reply